
|Videos|June 20, 2011
Dr. Kris Discusses the Imatinib GIST Clinical Trial
Author(s)Mark G. Kris, MD, FASCO
Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial
Advertisement
Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center Discusses the Imatinib (Gleevec) gastrointestinal stromal tumors (GIST) Clinical Trial.
Dr. Kris says in a GIST clinical trial, researchers compared one year of adjuvant post-surgery imatinib to three years of adjuvant post-surgery imatinib and found a significant improvement in cancer free survival and in overall survival. By taking a medicine for two more years (four pills a day), patients stayed free of cancer and lived longer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5



































